Suppr超能文献

嘧啶酮 D1 多巴胺受体正变构调节剂的开发。

Development of pyrimidone D1 dopamine receptor positive allosteric modulators.

机构信息

Molecular Neuropharmacology Section, NINDS, National Institutes of Health, Bethesda, MD, United States.

Specialized Chemistry Center, University of Kansas, Lawrence, KS, United States.

出版信息

Bioorg Med Chem Lett. 2021 Jan 1;31:127696. doi: 10.1016/j.bmcl.2020.127696. Epub 2020 Nov 19.

Abstract

MLS1082 is a structurally novel pyrimidone-based D1-like dopamine receptor positive allosteric modulator. Potentiation of D1 dopamine receptor (D1R) signaling is a therapeutic strategy for treating neurocognitive disorders. Here, we investigate the relationship between D1R potentiation and two prominent structural features of MLS1082, namely the pendant N-aryl and C-alkyl groups on the pyrimidone ring. To this end, we synthesized 24 new analogues and characterized their ability to potentiate dopamine signaling at the D1R and the closely related D5R. We identified structure-activity relationship trends for both aryl and alkyl modifications and our efforts afforded several analogues with improvements in activity. The most effective analogues demonstrated an approximately 8-fold amplification of dopamine-mediated D1R signaling. These findings advance the understanding of structural moieties underlying the activity of pyrimidone-based D1R positive allosteric modulators.

摘要

MLS1082 是一种结构新颖的嘧啶酮类 D1 样多巴胺受体正变构调节剂。增强 D1 多巴胺受体 (D1R) 信号转导是治疗神经认知障碍的一种治疗策略。在这里,我们研究了 D1R 增强作用与 MLS1082 两个突出结构特征之间的关系,即嘧啶酮环上的悬垂 N-芳基和 C-烷基。为此,我们合成了 24 种新的类似物,并研究了它们在 D1R 和密切相关的 D5R 上增强多巴胺信号的能力。我们确定了芳基和烷基修饰的构效关系趋势,我们的努力提供了一些具有活性改善的类似物。最有效的类似物表现出多巴胺介导的 D1R 信号的约 8 倍放大。这些发现加深了对基于嘧啶酮的 D1R 正变构调节剂活性的结构部分的理解。

相似文献

1
Development of pyrimidone D1 dopamine receptor positive allosteric modulators.
Bioorg Med Chem Lett. 2021 Jan 1;31:127696. doi: 10.1016/j.bmcl.2020.127696. Epub 2020 Nov 19.
2
Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics.
Curr Top Med Chem. 2019;19(16):1365-1380. doi: 10.2174/1568026619666190712210903.
3
Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.
ACS Chem Neurosci. 2015 Apr 15;6(4):681-92. doi: 10.1021/acschemneuro.5b00020. Epub 2015 Feb 20.
5
Identification of Positive Allosteric Modulators of the D Dopamine Receptor That Act at Diverse Binding Sites.
Mol Pharmacol. 2018 Oct;94(4):1197-1209. doi: 10.1124/mol.118.113175. Epub 2018 Aug 1.
6
Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders.
Adv Pharmacol. 2019;86:273-305. doi: 10.1016/bs.apha.2019.06.001. Epub 2019 Jul 13.
7
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.
Schizophr Bull. 2022 Jan 21;48(1):199-210. doi: 10.1093/schbul/sbab095.
8
Computational insights into ligand-induced G protein and β-arrestin signaling of the dopamine D1 receptor.
J Comput Aided Mol Des. 2023 Jun;37(5-6):227-244. doi: 10.1007/s10822-023-00503-7. Epub 2023 Apr 15.
9
The cooperative roles of the dopamine receptors, D1R and D5R, on the regulation of renal sodium transport.
Kidney Int. 2014 Jul;86(1):118-26. doi: 10.1038/ki.2014.5. Epub 2014 Feb 19.

引用本文的文献

1
The Molecular Mechanism of Positive Allosteric Modulation at the Dopamine D1 Receptor.
Int J Mol Sci. 2023 Aug 16;24(16):12848. doi: 10.3390/ijms241612848.
2
The molecular mechanism of positive allosteric modulation at the dopamine D1 receptor.
bioRxiv. 2023 Jul 30:2023.07.27.550907. doi: 10.1101/2023.07.27.550907.
3
Loss-of-Function Variants in in Infantile Parkinsonism-Dystonia.
Cells. 2023 Mar 30;12(7):1046. doi: 10.3390/cells12071046.
4
Ligand recognition and biased agonism of the D1 dopamine receptor.
Nat Commun. 2022 Jun 8;13(1):3186. doi: 10.1038/s41467-022-30929-w.
5
The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.
Front Pharmacol. 2022 Mar 9;13:847788. doi: 10.3389/fphar.2022.847788. eCollection 2022.

本文引用的文献

2
Novel Strategies To Activate the Dopamine D Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation.
J Med Chem. 2019 Jan 10;62(1):128-140. doi: 10.1021/acs.jmedchem.8b01767. Epub 2018 Dec 27.
3
Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor.
Mol Pharmacol. 2018 Oct;94(4):1232-1245. doi: 10.1124/mol.118.112649. Epub 2018 Aug 15.
4
Identification of Positive Allosteric Modulators of the D Dopamine Receptor That Act at Diverse Binding Sites.
Mol Pharmacol. 2018 Oct;94(4):1197-1209. doi: 10.1124/mol.118.113175. Epub 2018 Aug 1.
6
Emerging paradigms in GPCR allostery: implications for drug discovery.
Nat Rev Drug Discov. 2013 Aug;12(8):630-44. doi: 10.1038/nrd4052.
7
The neuropsychopharmacology of fronto-executive function: monoaminergic modulation.
Annu Rev Neurosci. 2009;32:267-87. doi: 10.1146/annurev.neuro.051508.135535.
8
Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling.
Neuropharmacology. 2008 Jun;54(7):1051-61. doi: 10.1016/j.neuropharm.2008.02.011. Epub 2008 Feb 21.
9
The dopaminergic system in hypertension.
Clin Sci (Lond). 2007 Jun;112(12):583-97. doi: 10.1042/CS20070018.
10
Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory.
Nat Neurosci. 2007 Mar;10(3):376-84. doi: 10.1038/nn1846. Epub 2007 Feb 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验